Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture
NCT ID: NCT02299830
Last Updated: 2014-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2014-12-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The four techniques areļ¼
* cryotherapy
* argon plasma coagulation
* stent
* snare
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cryotherapy
give the cases whose central airway stricture were caused by soft neoplasm tissues cryotherapy
cryotherapy
use cryotherapy to delete soft neoplasm tissue in the airway
argon plasma coagulation
give the cases whose central airway stricture were caused by hard neoplasm tissues argon plasma coagulation
argon plasma coagulation
use argon plasma coagulation to delete hard neoplasm tissue in the airway
stent
give the cases whose central airway stricture were caused by neoplasm compression stent placement
stent placement
use stent placement to open the airway compressed by out neoplasm
snare
give the cases whose central airway stricture were caused by polypoid neoplasm tissues snare
deletion tumor tissue by snare
use snare to delete polypoid neoplasm tissue in the airway
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cryotherapy
use cryotherapy to delete soft neoplasm tissue in the airway
argon plasma coagulation
use argon plasma coagulation to delete hard neoplasm tissue in the airway
stent placement
use stent placement to open the airway compressed by out neoplasm
deletion tumor tissue by snare
use snare to delete polypoid neoplasm tissue in the airway
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* the degree of stenosis is above 50%
* estimated survival duration is longer than 3 months
* received no treatment one month before
* can understand the statement informed consent
* agree to enroll in the study
Exclusion Criteria
* not malignant neoplasm caused central airway stenosis
* not central airway stenosis
* existence of lumina collapse or twisting
* severe arrhythmia, myocardial ischemia or hypertensive crisis
* coagulation disorders
* existence of severe organ disfunction
* allergic to anesthesia drugs
* refuse to participate the study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changhai Hospital
OTHER
The First Affiliated Hospital of Guangzhou Medical University
OTHER
Xinqiao Hospital of Chongqing
OTHER
China Meitan General Hospital
OTHER
Micro-Tech (Nanjing) Co., Ltd.
INDUSTRY
Tang-Du Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Faguang Jin, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Tang-Du Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tangdu Hospital
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NO.201402024
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
CAO-NO.201402024-malignant1
Identifier Type: -
Identifier Source: org_study_id